Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
November 27, 2012LifeMap Sciences, a Subsidiary of BioTime, Inc., Launches LifeMap Discovery™: A Database of Human Cellular Life for the Field of Regenerative Medicine
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 27, 2012-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the launch of LifeMap Discovery™ (discovery.lifemapsc.com), a state-of-the-art roadmap of embryonic development and stem cell biology. The platform integrates embryonic development and stem cell biology with molecular, cellular, anatomical, and disease-related information, and provides data-mining capabilities and b... 
Printer Friendly Version
November 20, 2012LifeMap Sciences, a Subsidiary of BioTime, Signs Definitive Distribution Agreement with ProSpec-Tany TechnoGene
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 20, 2012-- LifeMap Sciences, Inc. a subsidiary of BioTime, Inc. (NYSE MKT: BTX) announced today that it has signed a definitive distribution agreement with ProSpec-Tany TechnoGene Ltd. (ProSpec). In the beginning of 2013, LifeMap Sciences will be offering more than a 1000 recombinant proteins and antibodies, many of which are related to stem cell research, such as growth factors, signaling molecules, differentia... 
Printer Friendly Version
November 19, 2012LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.09
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 19, 2012-- LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards®, Version 3.09, on November 18, 2012. The new release is available at www.genecards.org. LifeMap Sciences holds the exclusive worldwide license to market GeneCards® from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science. GeneCa... 
Printer Friendly Version
November 01, 2012BioTime Subsidiary OrthoCyte Corporation Announces the Appointment of Francois Binette as Vice President
Adds senior executive with significant experience in developing cell-based orthopedic products ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 1, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OrthoCyte Corporation today announced the appointment of Francois Binette, PhD, as OrthoCyte’s Vice President of Research and Business Development. Dr. Binette’s primary focus will be to develop and partner near- and long-term product opportuniti... 
Printer Friendly Version
October 23, 2012BioTime’s Subsidiary LifeMap Sciences, Inc. Announces the Launch of MalaCards - A Database of Human Diseases
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 23, 2012-- BioTime, Inc. (NYSE MKT: BTX) and LifeMap Sciences, Inc. announce the launch of MalaCards, a new database of human diseases that is based on their leading GeneCards® platform. MalaCards (www.malacards.org/) contains computerized “cards” classifying information relating to a wide array of human diseases. This novel research tool will aid researchers in studying the roles of genes and cells in di... 
Printer Friendly Version
October 19, 2012LifeMap Sciences, Inc. Announces Addition to Board of Directors and Provides Update on Product Portfolio Development
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 19, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary, LifeMap Sciences, Inc., today announced the appointment of Louis E. Silverman to LifeMap Sciences’ board of directors. Mr. Silverman is an experienced health care executive with board level and operating experience in health care IT, pharmaceuticals, home health care, worker’s compensation managed care and revenue cycle management. From ... 
Printer Friendly Version
August 01, 2012BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office of the Chief Scientist
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Aug. 1, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has been awarded a grant for 2012 of 5.04 million Shekels (approximately $1.33 million) from Israel’s Office of the Chief Scientist (OCS) to help finance the development of OpRegen®, a cell-based therapeutic product in development by Cell Cure for the treatment... 
Printer Friendly Version
July 26, 2012BioTime Subsidiary LifeMap Sciences, Inc. Announces Financing of Up to $3 Million from Share Exchange Agreement
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 26, 2012-- BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences, Inc. (“LifeMap”) today announced that LifeMap entered into a Share Exchange and Contribution Agreement with Alfred D. Kingsley and a company that he controls, Greenway Partners, L.P., pursuant to which Mr. Kingsley and Greenway agreed to contribute to LifeMap, in the aggregate, BioTime common shares having an aggregate value of not les... 
Printer Friendly Version
April 23, 2012BioTime's Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development
ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) announced today that David Warshawsky, Ph.D., CEO of BioTime's subsidiary LifeMap Sciences, Inc. will provide an update on product development at an investor meeting in New York City today. Dr. Warshawsky will describe the origins of XenneX, a company that LifeMap has agreed to acquire, and the business strategy that led to its rapid rise to profitability. He will describe the GeneCards(R) database (http://www.genec... 
Printer Friendly Version
April 23, 2012BioTime's Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical Development of Vascular Progenitors for the Treatment of Age-Related Vascular Disease
ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) announced today that Steven Kessler, Ph.D., Vice President of Research at BioTime's subsidiary ReCyte Therapeutics, Inc. will provide an update on the development of reprogramming technologies and the generation of patient-specific vascular endothelial cells with essentially 100% purity using proprietary ACTCellerateTM technology. Dr. Kessler will also describe the use of ACTCellerateTM cell lines to manufacture spe... 
Printer Friendly Version
April 23, 2012BioTime's Subsidiary OncoCyte Corporation Provides Update on PanC-DxTM, and Related Diagnostic Products
- PanC-Dx on track for CE Marking in Europe by late 2014 - ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) announced today that Joseph Wagner, Ph.D., the CEO of BioTime's subsidiary OncoCyte Corporation and Karen B. Chapman, Ph.D., Director of Bioinformatics will provide updates on the development of the Company's pan-cancer diagnostic PanC-DxTM and related diagnostics at an investor meeting in New York City. PanC-DxTM ... 
Printer Friendly Version
April 23, 2012BioTime's Subsidiary Cell Cure Neurosciences, Ltd. Provides Update on OpRegen(R) Product Development
- Product development on track for IND filing during 2013 - ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTX) announced today that Charles S. Irving, Ph.D., the CEO of BioTime's subsidiary Cell Cure Neurosciences, Ltd. will provide an update on the development of OpRegen(R) at an investor meeting in New York City. In his presentation, Dr. Irving will describe the unmet medical needs and markets for the treatment of the ... 
Printer Friendly Version
March 22, 2012BioTime’s Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM
- An annual PanC-DxTM blood test could be the future alternative to the mammogram as the frontline screening method for breast cancer - ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 22, 2012-- BioTime, Inc. (NYSE Amex: BTX) and BioTime’s subsidiary OncoCyte Corporation today provided a progress report on the development of PanC-DxTM, a novel diagnostic device developed at BioTime and OncoCyte to detect the presence of various human cancers, i... 
Printer Friendly Version